Omicron-specific Sinopharm vaccine candidates cleared for clinical trial
Two COVID-19 vaccine candidates developed by units of China National Biotec Group (CNBG) to target the omicron variant were approved for clinical trials as boosters in Hong Kong, the Sinopharm subsidiary said on Saturday.
Scientists…
Read More...
Read More...